RT Journal Article
SR Electronic
T1 No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019 : A Retrospective Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.21.20066258
DO 10.1101/2020.04.21.20066258
A1 Wang, Dan
A1 Wang, Juan
A1 Jiang, Qunqun
A1 Yang, Juan
A1 Li, Jun
A1 Gao, Chang
A1 Jiang, Haiwei
A1 Ge, Lintong
A1 Liu, Yongming
YR 2020
UL http://medrxiv.org/content/early/2020/04/24/2020.04.21.20066258.abstract
AB Background Coronavirus disease 2019 (COVID-19) is becoming an increasing global health issue which has spread across the globe. We aimed to study the effect of corticosteroids in the treatment of adult inpatients with COVID-19.Methods A retrospective cohort of 115 consecutive adult COVID-19 patients admitted to The Third People’s Hospital of Hubei Province between Jan 18, 2020, and Feb 28, 2020 was analysed to study the effectiveness of corticosteroid. They were categorized according to whether or not corticosteroid therapy was given, and compared in terms of demographic characteristics, clinical features, laboratory indicators and clinical outcomes. The primary endpoint was defined as either mortality or intensive care unit (ICU) admission. Known adverse prognostic factors were used as covariates in multiple logistic regressions to adjust for their confounding effects on outcomes.Results Among 115 patients, 73 patients (63.5%) received corticosteroid. The levels of age, C-reactive protein, D-dimer and albumin were similar in both groups. The corticosteroid group had more adverse outcomes (32.9% vs. 11.9%) and statistically significant differences were observed (p=0.013). In multivariate analysis, corticosteroid treatment was associated with a 2.155-fold increase in risk of either mortality or ICU admission, although not statistically significant.Conclusion No evidence suggests that adult patients with COVID-19 will benefit from corticosteroids, and they might be more likely to be harmed with such treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.COVID-19coronavirus disease 2019SARS-CoV-2severe acute respiratory syndrome coronavirus 2WHOWorld Health OrganizationARDSacute respiratory distress syndromeICUintensive care unitRT-PCRreal-time reverse-transcriptase polymerase-chain-reactionMERSmiddle east respiratory syndromeIQRinterquartile rangeCK-MBCreatine kinase-muscle and brain typeESRErythrocyte sedimentation rate.